This EMCREG-International Satellite Symposium highlights immediate interventions for three types of life-threatening bleeding in patients on an anticoagulant: intracranial hemorrhage, gastrointestinal bleeding and trauma-related bleeding. The faculty for this CME-certified event includes experts who will provide didactic and case study presentations. Plus, the faculty will also participate in an interactive panel discussion with the audience. This enduring activity was originally presented as a satellite symposium which was held during the EUSEM 2022 Congress in Berlin, Germany.

This EMCREG-International Satellite Symposium highlights immediate interventions for three types of life-threatening bleeding in patients on an anticoagulant: intracranial hemorrhage, gastrointestinal bleeding and trauma-related bleeding. The faculty for this CME-certified event includes experts who will provide didactic and case study presentations. Plus, the faculty will also participate in an interactive panel discussion with the audience. This enduring activity was originally presented as a satellite symposium which was held during the EUSEM 2022 Congress in Berlin, Germany.

This EMCREG-International Satellite Symposium highlights immediate interventions for three types of life-threatening bleeding in patients on an anticoagulant: intracranial hemorrhage, gastrointestinal bleeding and trauma-related bleeding. The faculty for this CME-certified event includes experts who will provide didactic and case study presentations. Plus, the faculty will also participate in an interactive panel discussion with the audience. This enduring activity was originally presented as a satellite symposium which was held during the EUSEM 2022 Congress in Berlin, Germany.

Can we apply the new, more durable treatments in diabetic macular edema and neovascular age-related macular degeneration to the treatment of our patients with diabetic retinopathy? Join Dr. Peter Campochiaro and Dr. Roger Goldberg as they discuss ways these new approaches could benefit even more patients.

Cardiac contractility modulation (CCM) is a novel, approved, implantable therapy that significantly improves heart failure symptoms, exercise tolerance, and quality of life while reducing the rate of heart failure hospitalizations. Find out why you should consider sending your patients with NYHA Class III heart failure who are not responding to guideline-directed medical therapy directly to an electrophysiologist for device implantation.

Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and García-Foncillas outline current biomarkers and the importance of testing to optimize patient outcomes. Your patients will thank you for tuning in!

Patients with congenital heart disease are increasingly surviving into adulthood. For patients with single ventricle anatomy, pulmonary blood flow is dependent on central venous pressure with little or no ventricular support. Patients who have undergone Fontan surgery and progress to adulthood frequently develop increased pulmonary vascular resistance, which impacts ventricular function in a precapillary pulmonary hypertension phenotype.

This court case will explore the central question should these patients be placed on Group 1 vasodilator therapy. This pro/con debate will place you, the audience, in the role of the juror to decide the outcome. Evidence is presented, and expert witnesses queried the pluses and minuses of this therapeutic approach to maintaining physical function and quality of life in Fontan patients.

Patients with congenital heart disease are increasingly surviving into adulthood. For patients with single ventricle anatomy, pulmonary blood flow is dependent on central venous pressure with little or no ventricular support. Patients who have undergone Fontan surgery and progress to adulthood frequently develop increased pulmonary vascular resistance, which impacts ventricular function in a precapillary pulmonary hypertension phenotype.

This court case will explore the central question should these patients be placed on Group 1 vasodilator therapy. This pro/con debate will place you, the audience, in the role of the juror to decide the outcome. Evidence is presented, and expert witnesses queried the pluses and minuses of this therapeutic approach to maintaining physical function and quality of life in Fontan patients.

Patients with congenital heart disease are increasingly surviving into adulthood. For patients with single ventricle anatomy, pulmonary blood flow is dependent on central venous pressure with little or no ventricular support. Patients who have undergone Fontan surgery and progress to adulthood frequently develop increased pulmonary vascular resistance, which impacts ventricular function in a precapillary pulmonary hypertension phenotype.

This court case will explore the central question should these patients be placed on Group 1 vasodilator therapy. This pro/con debate will place you, the audience, in the role of the juror to decide the outcome. Evidence is presented, and expert witnesses queried the pluses and minuses of this therapeutic approach to maintaining physical function and quality of life in Fontan patients.

tbd